IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i5d10.1007_s41669-024-00503-9.html
   My bibliography  Save this article

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

Author

Listed:
  • Diana Beatriz Bayani

    (National University of Singapore)

  • Yihao Clement Lin

    (Tan Tock Seng Hospital)

  • Chandramouli Nagarajan

    (Singapore General Hospital)

  • Melissa G. Ooi

    (National University Cancer Institute)

  • Allison Ching Yee Tso

    (Tan Tock Seng Hospital)

  • John Cairns

    (London School of Hygiene and Tropical Medicine)

  • Hwee Lin Wee

    (National University of Singapore)

Abstract

Background and Objective This study aimed to assess the cost-effectiveness of two regimens regarded as the standard of care for the treatment of newly diagnosed, transplant-ineligible multiple myeloma in Singapore: (1) daratumumab, lenalidomide, and dexamethasone and (2) bortezomib, lenalidomide, and dexamethasone. Additionally, it aimed to explore potential strategies to manage decision uncertainty and mitigate financial risk. Methods A cost-effectiveness analysis from the healthcare system perspective was conducted using a partitioned survival model to estimate lifetime costs and quality-adjusted life years (QALYs) associated with daratumumab-based treatment and the bortezomib-based regimen. The analysis used data from the MAIA and SWOG S0777 trials and incorporated local real-world data where available. Sensitivity analyses were performed to evaluate the robustness of the findings, and a risk analysis was conducted to analyze various payer strategies in terms of their payer strategy and uncertainty burden (P-SUB), which account for the decision uncertainty and the additional cost of choosing a suboptimal intervention. Results The incremental cost-effectiveness ratio (ICER) for daratumumab, lenalidomide, and dexamethasone (DRd) compared with bortezomib, lenalidomide, and dexamethasone (VRd) was US $90,364 per QALY gained. The results were sensitive to variations in survival for DRd, postprogression treatment costs, cost of hospice care, and hazard ratio for progression-free survival. The scenarios explored indicated that structural assumptions, such as the time horizon of the analysis, significantly influenced the results due to uncertainties arising from immature trial data and treatment efficacy over time. Among the various payer strategies compared, an upfront price discount for daratumumab emerged as the best approach with the lowest P-SUB at US $14,708. Conclusion In conclusion, this study finds that daratumumab as a first-line treatment for myeloma exceeds the cost-effectiveness threshold considered in this evaluation. An upfront price reduction is the recommended strategy to manage uncertainties and mitigate financial risks. These findings highlight the importance of targeted payer strategies to address specific types and sources of uncertainty.

Suggested Citation

  • Diana Beatriz Bayani & Yihao Clement Lin & Chandramouli Nagarajan & Melissa G. Ooi & Allison Ching Yee Tso & John Cairns & Hwee Lin Wee, 2024. "Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers," PharmacoEconomics - Open, Springer, vol. 8(5), pages 651-664, September.
    • Handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00503-9
    DOI: 10.1007/s41669-024-00503-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-024-00503-9
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-024-00503-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Alan Brennan & Samer Kharroubi & Anthony O'Hagan & Jim Chilcott, 2007. "Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms," Medical Decision Making, , vol. 27(4), pages 448-470, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mehdi Najafzadeh & Carlo Marra & Eleni Galanis & David Patrick, 2009. "Cost Effectiveness of Herpes Zoster Vaccine in Canada," PharmacoEconomics, Springer, vol. 27(12), pages 991-1004, December.
    2. Wei Fang & Zhenru Wang & Michael B. Giles & Chris H. Jackson & Nicky J. Welton & Christophe Andrieu & Howard Thom, 2022. "Multilevel and Quasi Monte Carlo Methods for the Calculation of the Expected Value of Partial Perfect Information," Medical Decision Making, , vol. 42(2), pages 168-181, February.
    3. Susan Griffin & Nicky J. Welton & Karl Claxton, 2010. "Exploring the Research Decision Space: The Expected Value of Information for Sequential Research Designs," Medical Decision Making, , vol. 30(2), pages 155-162, March.
    4. Straub, Daniel & Ehre, Max & Papaioannou, Iason, 2022. "Decision-theoretic reliability sensitivity," Reliability Engineering and System Safety, Elsevier, vol. 221(C).
    5. Yunpeng Sun & Daniel W. Apley & Jeremy Staum, 2011. "Efficient Nested Simulation for Estimating the Variance of a Conditional Expectation," Operations Research, INFORMS, vol. 59(4), pages 998-1007, August.
    6. Oakley, Jeremy E. & Brennan, Alan & Tappenden, Paul & Chilcott, Jim, 2010. "Simulation sample sizes for Monte Carlo partial EVPI calculations," Journal of Health Economics, Elsevier, vol. 29(3), pages 468-477, May.
    7. Laura McCullagh & Cathal Walsh & Michael Barry, 2012. "Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting," PharmacoEconomics, Springer, vol. 30(10), pages 941-959, October.
    8. Brett Houlding & Frank P. A. Coolen & Donnacha Bolger, 2015. "A Conjugate Class of Utility Functions for Sequential Decision Problems," Risk Analysis, John Wiley & Sons, vol. 35(9), pages 1611-1622, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00503-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.